Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Background: Comprehensive description of ketamine's molecular binding profile becomes increasingly pressing as use in real-life patient cohorts widens. Animal studies attribute a significant role in the substance's antidepressant effects to the serotonergic system. The serotonin transporter is a highly relevant target in this context, because it is central to depressive pathophysiology and treatment. This is, to our knowledge, the first study investigating ketamine's serotonin transporter binding in vivo in humans. Methods: Twelve healthy subjects were assessed twice using [11C]DASB positron emission tomography. A total of 0.50 mg/kg bodyweight ketamine was administered once i.v. prior to the second positron emission tomography scan. Ketamine plasma levels were determined during positron emission tomography. Serotonin transporter nondisplaceable binding potential was computed using a reference region model, and occupancy was calculated for 4 serotonin transporter-rich regions (caudate, putamen, thalamus, midbrain) and a whole-brain region of interest. Results: After administration of the routine antidepressant dose, ketamine showed <10% occupancy of the serotonin transporter, which is within the test-retest variability of [11C]DASB. A positive correlation between ketamine plasma levels and occupancy was shown. Conclusions: Measurable occupancy of the serotonin transporter was not detectable after administration of an antidepressant dose of ketamine. This might suggest that ketamine binding of the serotonin transporter is unlikely to be a primary antidepressant mechanism at routine antidepressant doses, as substances that facilitate antidepressant effects via serotonin transporter binding (e.g., selective serotonin reuptake inhibitors) show 70% to 80% occupancy. Administration of high-dose ketamine is widening. Based on the positive relationship we find between ketamine plasma levels and occupancy, there is a need for investigation of ketamine's serotonin transporter binding at higher doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. (a) No measurable occupancy of the serotonin transporter (SERT) after 0.50 mg/kg bodyweight ketamine. [11C]DASB nondisplaceable binding potential (BPND) decreased numerically from positron emission tomography (PET) 1 (left, before ketamine application) to PET 2 (right, after application of the standard antidepressant dose of 0.50 mg/kg bodyweight ketamine) in the caudate, putamen, and thalamus. Mean occupancy values ± SD of the SERT were 5.86±21.88, 2.70±13.76, and 1.11±23.27, respectively. Results were interpreted as a lack of measurable binding, because occupancy values are within [11C]DASB test-retest variability (Kranz et al., 2015) (see supplement). Color bar represents [11C]DASB BPND. Slices at z=10 (caudate), z=6 (putamen), and z=12 (thalamus). For [11C]DASB BPND and occupancy values see Table 1. (b) Correlation between ketamine plasma levels and SERT occupancy. Ketamine plasma levels assessed after ketamine administration during PET correlated with SERT occupancy within the caudate and putamen (caudate 20 min: P=.042; 30 min: P=.018; putamen 30 min: P=.031, all uncorr., min indicate time after start of PET measurement). Though the correlations are influenced by outliers, these findings might suggest that ketamine may bind the SERT when levels are higher, for example, when ketamine is administered at higher doses or depending on differences in metabolism (Zarate et al., 2012; Zhao et al., 2012). Correlation analyses with ketamine plasma levels drawn 30 minutes after PET start are depicted. Correlations may be significant at this time point, as ketamine kinetics are known to switch from the distribution to elimination phase around this time (Hijazi et al., 2003). *Indicates statistical significance of correlations (P<.05, uncorrected). For occupancy values and ketamine plasma levels, see Tables 1 and 2.](https://figures.cochat.ai/paper-figures/b71e4f80170d4f9788e19a4b402fcca0/assessment-of-ketamine-binding-of-the-serotonin-transporter-in-humans-with-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This study did not observe significant occupancy of ketamine at SERT in the caudate, putamen, thalamus, and whole brain ROIs.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Spies et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“, 2015) and raised questions as to how often the substance should be applied (Murrough et al., 2013) and in combination with what other potentiating or effect-stabilizing treatments (Chiu et al.”
BackgroundIchise, M., Liow, J.-S., Lu, J.-Q., Takano, A., Model, K., Toyama, H., Suhara, T., Suzuki, K., Innis, R. B., & Carson, R. E. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000085441.37552.ca · Cited by 650
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468 · cited 1×
“As an NMDA receptor antagonist (Lener et al., 2016), ketamine modulates the glutamatergic system, though it has also been shown to effect dopaminergic (Li et al.”
BackgroundKapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459 · cited 1×
“It has, however, been suggested that ketamine may bind 5-HT2 receptors (Kapur and Seeman, 2002; Waelbers et al., 2013).”
BackgroundMeyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Bel, N., & Artigas, F. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90292-c · Cited by 269
Normative database of the serotonergic system in healthy subjects using multi-tracer PET
Savli, M., Bauer, A., Mitterhauser, M., Ding, Y.-S., Hahn, A., Kroll, T., Neumeister, A., Haeusler, D., Ungersboeck, J., Henry, S., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.07.001 · Cited by 251
Self-citationWilson, A. A., Ginovart, N., Schmidt, M., Meyer, J. H., Threlkeld, P. G., & Houle, S. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000079i · Cited by 249
Meta-analysis of molecular imaging of serotonin transporters in major depression
Gryglewski, G., Lanzenberger, R., Kranz, G. S., & Cumming, P. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.82 · Cited by 227 · cited 1×
“A potential role for the SERT is based on the antidepressant efficacy of selective serotonin reuptake inhibitors (SSRIs) and numerous studies showing changes to the SERT in depression (Gryglewski et al., 2014; Spies et al., 2015).”
BackgroundSelf-citationRegional distribution of serotonin transporter protein in postmortem human brain
Kish, S. J., Furukawa, Y., Chang, L.-J., Tong, J., Ginovart, N., Wilson, A., Houle, S., & Meyer, J. H. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.10.001 · Cited by 179
The serotonin transporter in psychiatric disorders: insights from PET imaging
Spies, M., Knudsen, G. M., Lanzenberger, R., & Kasper, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00232-1 · Cited by 177 · cited 1×
“A potential role for the SERT is based on the antidepressant efficacy of selective serotonin reuptake inhibitors (SSRIs) and numerous studies showing changes to the SERT in depression (Gryglewski et al., 2014; Spies et al., 2015).”
BackgroundSelf-citationKetamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
Fukumoto, K., Iijima, M., & Chaki, S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.233 · Cited by 174
Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
Romeo, B., Choucha, W., Fossati, P., & Rotge, J.-Y. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.10.032 · Cited by 151 · cited 3×
“50 mg/kg bodyweight racemic ketamine was chosen as this is the generally accepted and thoroughly investigated subanesthetic, antidepressant dose (Perry et al., 2007; Romeo et al., 2015).”
MethodInfluentialZhao, X., Venkata, S. L. V., Moaddel, R., Luckenbaugh, D. A., Brutsche, N. E., Ibrahim, L., Zarate Jr, C. A., Mager, D. E., & Wainer, I. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04198.x · Cited by 137
Pham, T. H., Mendez-David, I., Defaix, C., Guiard, B. P., Tritschler, L., David, D. J., & Gardier, A. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.010 · Cited by 136
Hevers, W., Hadley, S. H., Lüddens, H., & Amin, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5443-07.2008 · Cited by 128
Location of the Antidepressant Binding Site in the Serotonin Transporter
Andersen, J., Taboureau, O., Hansen, K. B., Olsen, L., Egebjerg, J., Strømgaard, K., & Kristensen, A. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806907200 · Cited by 123
Lanzenberger, R., Baldinger, P., Hahn, A., Ungersboeck, J., Mitterhauser, M., Winkler, D., Micskei, Z., Stein, P., Karanikas, G., Wadsak, W., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.93 · Cited by 120
Self-citationParsey, R. V., KENT, J. M., Oquendo, M. A., Richards, M., Pratap, M., Cooper, T. B., Arango, V., & Mann, J. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.010 · Cited by 120
Psychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
Hijazi, Y., Bodonian, C., Bolon, M., Salord, F., & Boulieu, R. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeg028 · Cited by 115
Serotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113 · cited 1×
“Subcortical regions with high SERT expression (Saulin et al., 2012; Savli et al., 2012) shown to be relevant in other SERT occupancy studies were investigated (Meyer et al.”
BackgroundSelf-citationHow does ketamine elicit a rapid antidepressant response?
Kavalali, E. T., & Monteggia, L. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.005 · Cited by 111
Cusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N., Eikermann, M., Durham, K., Swee, M. B., Chang, T., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 111
Administration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110
Self-citationAnderson, I. M., Blamire, A., Branton, T., Clark, R., Downey, D., Dunn, G., Easton, A., Elliott, R., Elwell, C., Hayden, K., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30077-9 · Cited by 108
Fukumoto, K., Iijima, M., & Chaki, S. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3378-0 · Cited by 107
Celada, P., & Artigas, F. (1993) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00166940 · Cited by 107
Spindelegger, C., Lanzenberger, R. R., Wadsak, W., Mien, L., Stein, P., Mitterhauser, M., Moser, U., Holik, A., Pezawas, L., Kletter, K., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.35 · Cited by 100
Self-citationdu Jardin, K. G., Liebenberg, N., Müller, H. K., Elfving, B., Sánchez, C., & Wegener, G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4327-5 · Cited by 93
High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People
Kranz, G. S., Wadsak, W., Kaufmann, U., Savli, M., Baldinger, P., Gryglewski, G., Haeusler, D., Spies, M., Mitterhauser, M., Kasper, S., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.09.010 · Cited by 89
Self-citationYamanaka, H., Yokoyama, C., Mizuma, H., Kurai, S., Finnema, S. J., Halldin, C., Doi, H., & Onoe, H. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.112 · Cited by 84
Ketamine stereoselectively inhibits rat dopamine transporter
Nishimura, M., & Sato, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00688-6 · Cited by 79
Ketamine for Depression, 3: Does Chirality Matter?: (Clinical and Practical Psychopharmacology)
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11681 · Cited by 78
Talbot, P. S., Frankle, W. G., Hwang, D., Huang, Y., Suckow, R. F., Slifstein, M., Abi‐Dargham, A., & Laruelle, M. (2005) · Synapse · doi:10.1002/syn.20105 · Cited by 77
Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 76
Li, Y., Zhu, Z. R., Ou, B. C., Wang, Y. Q., Tan, Z. B., Deng, C. M., Gao, Y., Tang, M., So, J. H., Mu, Y., et al. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.11.016 · Cited by 76
Chiu, C.-T., Scheuing, L., Liu, G., Liao, H.-M., Linares, G. R., Lin, D., & Chuang, D.-M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu102 · Cited by 66
Zhao, Y., & Sun, L. (2008) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2007.11.007 · Cited by 56
History, background, concepts and current use of comedication and polypharmacy in psychiatry
Möller, H. ‐., Seemüller, F., Schennach-Wolff, R., Stübner, S., Rüther, E., & Grohmann, R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000837 · Cited by 56
du Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.05.007 · Cited by 53
Radford, K. D., Park, T. Y., Lee, B. H., Moran, S., Osborne, L. A., & Choi, K. H. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.12.014 · Cited by 44
Effects of opioids on human serotonin transporters
Barann, M., Stamer, U. M., Lyutenska, M., Stüber, F., Bönisch, H., & Urban, B. W. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-1056-3 · Cited by 43
Martin, D. C., Introna, R. P. S., & Aronstam, R. S. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90329-8 · Cited by 41
Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects
Zhang, G.-F., Liu, W.-X., Qiu, L.-L., Guo, J., Wang, X.-M., Sun, H., Yang, J., & Zhou, Z. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.11.007 · Cited by 32
Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies
Lundquist, P., Wilking, H., Höglund, A. U., Sandell, J., Bergström, M., Hartvig, P., & Långström, B. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.12.001 · Cited by 31
Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications
Haeusler, D., Mien, L., Nics, L., Ungersboeck, J., Philippe, C., Lanzenberger, R. R., Kletter, K., Dudczak, R., Mitterhauser, M., & Wadsak, W. (2009) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2009.03.005 · Cited by 31
Self-citationBartova, L., Vogl, S. E., Stamenkovic, M., Praschak-Rieder, N., Naderi‐Heiden, A., Kasper, S. F., & Willeit, M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.021 · Cited by 30
Self-citationXu, A. J., Niciu, M. J., Lundin, N. B., Luckenbaugh, D. A., Ionescu, D. F., Richards, E. M., Voort, J. L. V., Ballard, E. D., Brutsché, N. E., Machado‐Vieira, R., et al. (2015) · Neural Plasticity · doi:10.1155/2015/858251 · Cited by 28
Yamamoto, S., Onoe, H., Tsukada, H., & Watanabe, Y. (2007) · Synapse · doi:10.1002/syn.20422 · Cited by 25
Optimization of [11C]DASB-synthesis: Vessel-based and flow-through microreactor methods
Ungersboeck, J., Philippe, C., Haeusler, D., Mitterhauser, M., Lanzenberger, R. R., Dudczak, R., & Wadsak, W. (2012) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2012.08.001 · Cited by 18
Self-citationWaelbers, T., Polis, I., Vermeire, S. T., Dobbeleir, A. A., Eersels, J. L. H., Spiegeleer, B. M. J. D., Audenaert, K., Slegers, G., & Peremans, K. Y. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114637 · Cited by 17
Wilson, A. A., Ginovart, N., Schmidt, M., Meyer, J. H., Threlkeld, P. G., & Houle, S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0003743 · Cited by 4
Cited by
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 120
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
“Ketamine also inhibits the reuptake of serotonin, dopamine and norepinephrine [47], although a recent positron emission tomography (PET) study found no evidence that ketamine treatment alters serotonin transporter occupancy [48].”
BackgroundJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Lavender, E., Hirasawa-Fujita, M., & Domino, E. F. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112631 · Cited by 58
Metadata
- Authors
- Spies, M., James, G. M., Berroterán-Infante, N., Ibeschitz, H., Kranz, G. S., Unterholzner, J., Godbersen, M., Gryglewski, G., Hienert, M., Jungwirth, J., Pichler, V., Reiter, B., Silberbauer, L., Winkler, D., Mitterhauser, M., Stimpfl, T., Hacker, M., Kasper, S., & Lanzenberger, R.
- Affiliations
- Ludwig Boltzmann Institute Applied Diagnostics (AT)
- Corresponding author
- Lanzenberger, Rupert
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-16
- Volume
- 21
- Issue
- 2
- Pages
- 145-153
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5793827
- OpenAlex
- W2765280907
- Cited by
- 34
- References
- 61
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 3
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (23741)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, serotonin transporter, [11C]DASB, antidepressant mechanism, depression, caudate nucleus, putamen, thalamus, midbrain
- MeSH terms
- Adult, Aniline Compounds, Antidepressive Agents, Humans, Ketamine, Male, Mesencephalon, Sulfides, Thalamus, Neostriatum, Serotonin Agents, Positron-Emission Tomography, Serotonin Plasma Membrane Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.